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Background
The stroke is known as an acute risk of cerebral perfusion 
or an unexpected beginning of a neurological deficit, 
which resulted from acute focal damage on the core 
nervous system for vascular reasons.1,2 Besides, the stroke 
has been one of the common causes for adult disability 
with an annual rate of approximately 17 million patients, 
making stroke as the second prominent reason for death 
followed by coronary artery disease.3 Also, it imposes 
considerable economic adverse effects on the governments 
and families to provide health care services, medications, 
and rehabilitation, forcing a productivity loss of about $33 
per year.4 The stoke is forecasted to cause 6.2% of expenses 
for medications, particularly in developed nations. By 
2020 in developed countries, it has predicted that stroke 
will be accountable for 6.2% of the total burden of illness.5 
Surprisingly, nearly 85% of risen strokes have ischemic 
causes, and just 15% of such issues are accompanied by or 
produced by hemorrhage.6 Therefore, given the provided 
statistics and undeniable importance of ischemic stroke, 
early recognition and consequently appropriate treatment 
is in paramount of importance for prevention and 
minimization of morbidity and mortality. 
To this end, considering the causes of the ischemic 
stroke will be worthy of note. One of the prominent factors 
is known to be hypertension. Among youth, cardiac 
disease, coagulopathy disorders, carotid dissection, and 
illicit drug abuse considered as the main cause of stroke.7 
The ischemic stroke will diagnose through unexpected 
blood circulation loss in a specific portion of the brain, 
which will lead to neurologic dysfunction. The ischemic 
stroke has a conventional type, which is called acute 
ischemic stroke (AIS), and resulted from a thrombotic/
embolic occlusion of a cerebral artery.8 The higher risk 
of AIS will see with higher age, and this is while we 
are encounter enhanced incidence of AIS worldwide, 
particularly in developing nations.9 In terms of gender, 
AIS is more common among females with a predilection 
in premenopausal period.10,11 Such an increasing global 
trend of AIS incidences makes sense to employ better 
treatment approaches and techniques and improvement 
of AIS patients’ outcomes.12 Interestingly, there has been 
an association between risk factors as old age, severe 
neurological disability, not having a spouse, anemia, 
diabetes mellitus, and peripheral vascular disease and 
sores among patients suffering from AIS.13 
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Cerebrovascular disease is the second cause of death and the sixth cause of morbidity worldwide, 
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Besides, as the statistics show AIS as a significant medical 
event which influences annually 795 000 individuals 
around the world and provides catastrophic consequences 
for the corresponding patients, their families, and society,14 
it can conclude that quick recognition of stroke signs by 
the emergency medicine is undoubtedly a key action. 
Alike, time-dependent treatments may significantly 
change the neurologic sequelae of AIS. Every physician 
working in emergency medicine wards should bear the 
well-known statement “time is brain” in his mind while 
assessing and treating a patient with probable AIS.15
The pathophysiology for AIS has some simplicities and 
complexities. The reason for simplicities is that the first 
incidence will be the obstruction of an intra or extracranial 
vessel, impairing brain parenchyma blood supply leading 
to infarction. The occlusion may be arisen from an artery 
to artery embolism, which considerably originating from 
an internal carotid artery (ICA) plaque, or secondary to 
embolization of a clot from other sides as the heart is 
in paramount of importance which is usually as a result 
of occult or overt atrial fibrillation. On the other hand, 
the complexity observed; lots of diverse cellular outputs 
happen when there is a considerable low cerebral blood 
flow (CBF), leading to a cascade of ischemia in brain 
cellular parenchyma.16 The outcomes resulted from brain 
ischemia are different in their color, and subsequently, the 
difference in the temporal evolution of ischemic cascade 
regarding their neuroprotection elements is possible.17 
It can note that the mechanisms of ischemic injury are 
different in brain regions with little or no residual CBF 
than in areas having higher modest decreases. Also, the 
irreversibility of ischemic damage defers based on the 
presence of minimal preserved CBF in the areas which 
are named ischemic penumbra.18 Such a potentially 
salvageable area is the foundation for the treatment 
of AIS in the initial time of the ictus.19 In contrast, the 
ischemic core refers to an ischemic area that has already 
progressed to irreversibility. The two mentioned areas can 
approximate by advanced computed tomography (CT) 
as well as magnetic resonance imaging (MRI).20 As the 
ischemic damage progresses, the ischemic penumbra will 
shrinkage expansion of the core will be prominent, leading 
to irreversible damage.  Interestingly, the ratio ischemic 
penumbra to core area is variable among patients with the 
same location of vascular occlusion. This diversity might 
not relate due to the small-vessel lacunar infarct but 
seems to be appropriate for both larger vessel occlusions 
secondary to local atherosclerosis or cardiac embolism. 
Important factors as temperature, metabolic factors 
including glucose, and efficient collateral blood supply 
affect the evolution of the two areas.21 The emergent 
therapeutic interventions as the reestablishment of CBF 
to the ischemic area, enhancing collateral blood flow, 
maybe effective on the evolution of ischemic penumbra 
and compose a foundation for advanced AIS therapies 
and those which will develop. Nowadays, AIS has entered 
a significant era regarding the precise knowledge of basic 
pathophysiology of ischemic brain injury, advanced 
neuroimaging modalities, and the introduction of 
thrombolytic therapy to restore blood flow and improved 
non-medical care in patients suffering from AIS.8 
Also, the stroke will give rise to functional disability 
and death, and thus it will make AIS an emergency case 
requiring emergent intervention. There is no doubt that 
thrombolytic therapy as thrombolysis and endovascular 
revascularization were permanently in the lower level 
in patients with AIS compared to similar treatments in 
cardiology.22 
In such acute conditions, stroke management should 
be quickly exerted, in a way that the patients must be 
considered for Intravenous thrombolysis with tissue 
plasminogen activator (IV-tPA) within at most 4.5 hours 
as well as mechanical thrombectomy for a maximum 
duration of 6h. The conducted trials reveal the window to 
be able opening for mechanical thrombectomy at most 24 
hours of large vessel occlusion in certain cases.23
Methods
As the present study is a review work, the literature 
provided through looking up three authentic medical 
databases including Web of Science, PubMed and Science 
Direct with a focus on diverse Medical Subject Headings 
(MeSH) terms or subcategories accessible in each of the 
databases mentioned above, screening all relevant papers 
and books.
Results
History of Emergent Thrombectomy
On the eve of 2016, IV-tPA has taken into consideration as 
the goal therapeutic method in AIS management. Such a 
therapeutic strategy resulted from a trial conducted by the 
National Institute of Neurological Disorders and Stroke in 
1995, where the patients who underwent tIV-tPA therapy 
over 3 hours of initial symptoms had a higher possibility 
of 30% for not having a disability or minimal disability 
compared to placebo.24 According to the European 
Cooperative Acute Stroke Study III, such a therapeutic 
window then got longer up to 4.5 hours from symptom 
onset, revealing the same profits of administration of IV-
tPA for the duration of 3-4.5 hours.25
However, in case of significant cerebral artery occlusion 
as the involvement of the intracranial internal carotid 
artery or the first and second segment of the middle 
cerebral artery (M1, M2), the efficacy of IV-tPA was 
inefficient showing a recanalization rate of just 4%-30%.26 
In order to make the recanalization rate more efficient, 
endovascular mechanical thrombectomy introduced to 
evacuate acute thrombosis. The initial investigations on 
this approach revealed opposing findings which were 
justified by inappropriate sample size and suboptimal 
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endovascular devices, leading to a low recanalization 
rate.27–29 
Following advances in thrombectomy devices, releasing 
five successful trials in acute mechanical thrombectomy 
for ischemic stroke due to large-vessel occlusion in anterior 
circulation led to a significant change in the management 
of stroke.30–34 After that, emergent thrombectomy has 
globally considered as the leading standard for handling 
the patients with AIS originating by a significant vessel 
occlusion and is now advised in all instructions to be used 
for a major stroke.24
Advances in AIS Treatment Emphasizing on the 
Emergent Thrombectomy
In comparison to the former negative thrombectomy, 
one of the considerable advances was the introduction 
of newer stent retriever devices leading to a higher rate 
of recanalization. In this new trend, a nearly complete 
recanalization (TICI 2b/3) was realized among 59%-88% 
of patients, by analogy to intra-arterial tPA and first-
generation devices with an achievement among 25%-41% 
of patients.24 
The other thrombectomy device used in 2016 was the 
direct aspiration catheter (ADAPT technique) employing 
for removal of the thrombosis through a large-bore 
endovascular catheter. The multiple single-center series 
supported the ADAPT, demonstrating remarkable result, 
and even higher than previous stent retrievers.35 In 
addition to what mentioned above, the 2016 THERAPY 
trial was the only randomized investigation for 
comparison of aspiration thrombectomy against IV-tPA 
alone, terminating too soon regarding the limited sample 
size upon publication of the positive stent retriever trial 
which failed to reveal a considerable difference from 
aspiration thrombectomy benefits to merely intravenous 
thrombolysis.36
Similarly, Cerejo et al37 employed emergent mechanical 
thrombectomy in the management of AIS. This trial was 
conducted through the Mind frame Capture LP system 
and considered as an initial single-center experience. 
They aimed to offer their basic experiments with the 
Mind frame Capture LP device. This device designed for 
mechanical thrombectomy among small cerebral arteries. 
In the procedure, a retrospective chart review conducted 
of patients who underwent a Mind frame device assisted 
emergent thrombectomy. Their findings approved the 
safety and efficacy of the Mind frame device for prompt 
treatment of AISs comprising small-caliber intracranial 
vessels. 
Anadani et al38 argue that emergent carotid artery 
stenting along with mechanical thrombectomy, can 
be an effective treatment for the patients with AIS as a 
consequence of thrombosis in the anterior circulation. To 
this end, they studied the safety of emergent carotid artery 
stenting-mechanical thrombectomy method among 
society with a stroke under prior IV-tPA. Their results 
confirmed no association between emergent carotid 
artery stenting-mechanical thrombectomy and a higher 
risk of hemorrhagic transformation among patients 
receiving IV-tPA before the intervention.
Besides, a revolution in interventional therapeutic 
approaches in AIS realized applying stent-like 
thrombectomy devices named stent retrievers.39 Due 
to being quite retrievable, such devices provide the 
profits of both quick flow restoration and mechanical 
thrombectomy, and thus, great recanalization outcomes 
will realize with a rate of 90%. The similar investigations 
report desirable clinical findings for three months.40 Such 
an improvement can attribute to quick and efficient clot 
removal and the likelihood of temporary restoration flow.41 
Additionally, the application of stent retriever devices will 
be relevant to low symptomatic ICH and mortality rates. 
The latter shows the low rate of symptomatic ICH, as well 
as safe flow-restoration, means by an analogy to the older 
thrombectomy.42 In this approach, the target vessel entered 
with a 0.014-inch guidewire and a proper microcatheter 
with a size of 0.018-0.027 inches. The thrombus has 
crossed with the guidewire, and the microcatheter has 
distally located to the thrombus. The stent retriever is 
advanced to the distal end of the microcatheter. In the 
following, the microcatheter has got away to expand the 
stent retriever under fluoroscopy. A control angiogram 
conducted followed-by the prosperous unfolding of the 
device. The sizes of such devices vary 3.0×15-6.0×30 mm; 
nonetheless, commonly, a 6.0-mm device is employed. 
Upon a short while, the stent retriever receded with 
continuous aspiration. The scheme will iterate as long as a 
TICI grade of 2b or three is reached.43
For instance, among plenty of conducted relevant trials, 
like the first, we can refer to the study carried out in 
2014 entitled “Multicenter Randomized Clinical Trial of 
Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands” or MR CLEAN.29 Where 500 patients with 
AIS due to a  large vessel occlusion in anterior circulation 
confirmed with CTA presenting within 6 hours from ictus 
were included in the study to receive either endovascular 
therapy or ordinary medical care. 81.5% of patients 
were under endovascular intervention, of which 90.6% 
received rTPA before endovascular treatment. The 90-
day prognosis of the patients was statistically different 
between two groups, as 13.5% points (adjusted odds 
ratio 1.67) of mRs observed in the endovascular group. 
In a similar pattern, a provisional analysis of the rest 4 
EVT trials: ESCAPE,32 REVASCAT,31 EXTEND-IA trial 
(Extending the Time for Thrombolysis in Emergency 
Neurological Deficits–Intra-Arterial),33 and SWIFT-
PRIME34 revealed promising results. Exclusively, the 
ESCAPE and EXTEND-IA trials enrolled patients with a 
documented favorable penumbra region. The criterion for 
the existence of salvageable penumbra was assumed based 
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on adequate collateral circulation evident by multimodal 
in the ESCAPE trial and by the Rapid Processing of 
Perfusion and Diffusion software the EXTEND-IA group. 
In general, the median onset of endovascular procedure 
varied between 200-260 minutes, with a successful 
revascularization rate of 59%-88%. Although not overall, 
the mortality rate was reduced by up to 50% in the 
EXTEND-IA and ESCAPE trials. The HERMES (Highly 
Effective Reperfusion evaluated in Multiple Endovascular 
Stroke) trials, a recently published patient-level meta-
analysis including 1287 individuals from the 5 EVT 
landmark trials, confirmed the previous results. A 90-day 
disability was considerably lower in comparison to the 
control group (cOR 2.49, 95% confidence interval 1.76–
3.53; P<0.0001). The number required to treat with EVT 
for disability improvement by at least one point on mRS 
is 2.6. The patients’ characteristics have not disregarded 
(elderly, time from onset to randomization >300 
minutes, individuals not receiving recombinant tPA) and 
mortality, and sICH was not different between groups.42 
Another two other EVT trials including (THERAPY 
[The Randomized, Concurrent Controlled Trial to Assess 
the Penumbra System’s Safety and Effectiveness in the 
Treatment of Acute Stroke] and THRACE [Trial and Cost-
Effectiveness Evaluation of Intra-arterial Thrombectomy 
in Acute Ischemic Stroke])44,45 presented at the European 
Stroke Conference in 2015 revealed similar promising 
results.  Other trials (POSITIVE [Perfusion Imaging 
Selection of Ischemic Stroke Patients for Endovascular 
Therapy] and DAWN [Diffusion Weighted Imaging or 
Computerized Tomography Perfusion Assessment With 
Clinical Mismatch in the Triage of Wake Up and Late 
Presenting Strokes Undergoing Neurointervention]) 
have carried out aiming to expand the golden time of 
therapy which were promising by ≤12 and 24 hours, 
respectively.  Taking into all considerations, IV-tPA is 
still the first line of treatment within 4.5 hours of AIS 
symptoms. In case of documented LVO with a marked 
salvageable penumbra, emergent EVT should consider 
within the first 6 hours from ictus. However, it should 
be noted that only less than 10% of patients with AIS 
undergo endovascular procedures in the United States, 
even in well-trained stroke centers. The most important 
challenges in patient selection for endovascular therapy 
include lacunar infarct, stroke in evolution, large-vessel 
occlusion leading to severe ischemic infarct with a high 
NIHSS score, and unknown time of the onset which has 
mostly seen as wake-up stroke.  Wake-upstrokes constitute 
approximately 20% of all ischemic strokes and usually 
hampered of acute reperfusion therapy according to 
uncertain timing.46 A series of DEFUSE trials (Diffusion 
and Perfusion Imaging Evaluation for Understanding 
Stroke Evolution)47,48 introduced the application of 
perfusion imaging to evaluate the salvageable presence 
penumbra in patients referring to stroke center later than 
the golden time of treatment. Currently, DEFUSE-3 is 
under progress, including patients presented within ≤16 
hours of symptoms who are not a candidate for IV or IA 
tPA therapies. 
Additionally, the reports are suggestive of better 
prognosis for patients who admitted in a multidisciplinary 
stroke unit even for those who do not receive acute 
reperfusion therapy compared to individuals hospitalized 
in general neurology centers with a similar hospitalization 
period.49 
Similarly, Heit et al50 provided some evidence that 
proves the applicability of perfusion CT (PCT) imaging 
in preparing critical information for triage of AIS patients 
to EVT. Besides, they also showed that PCT could specify 
both ischemic penumbra and core infraction, and this 
is while those having any mismatch between these two 
mentioned areas will most probably be able to take 
advantage of EVT. Finally, they argue the usability of 
PCT in the identification and localization of large-vessel 
occlusions.
Despite all advantages of the stent retriever, clinical 
experiences have shown the positions which are resistant 
to recanalization efforts of that, including terminal 
ICA, middle cerebral artery bifurcation and trifurcation 
thrombosis as well as complicated thrombi configuration 
for which an alternative technique may be the direct 
aspiration of the thrombus. This approach made a 
prompt evolution in mechanical thrombectomy, is widely 
employed in plenty of clinical experiments. 51 Most 
recently, some newer aspiration means have been applied 
and taken into development, such as making a new 
variation in the distal inner diameters of the catheter; as a 
result, this approach is in some centers used as a primary 
technique for intracranial artery occlusion. The newer 
investigations revealed the aspiration technique with 
reasonable safety and effectiveness of the EVT method 
with clinical results compared with the approaches used 
in the stent retriever devices.52,53 As the main profits 
made by this approach, one can point to the short process 
time and considerable clinical outcomes.52 In the case 
of utilizing this approach, the thrombus passed with 
the microwire and microcatheter, and the aspiration 
catheter directly located in the thrombus proximal part. 
Both microwire and microcatheter will eliminate. A 
lack of backflow characterizes thrombosis entrapment. 
The catheter has then retrieved with constant negative 
pressure to avoid loss of thrombus. Following retrieval of 
each clot fragments, the procedure will iterate as long as 
the achievement of a TICI grade of ≥2 or 3.54 
In addition to the approaches mentioned above, tandem 
occlusions can state, which consists of simultaneous extra 
and intracranial stenosis of ICA. Although this technique 
is not conventional, it provides challenging therapeutic 
conditions considering the AIS.42 The mechanism of 
extracranial ICA segment occlusion is different from 
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other cerebrovascular processes. Here, the primary 
pathophysiology is ruptured atherosclerotic plaque 
and superimposed thrombus, which has seen in acute 
occlusion of the coronary arteries. Emergent stenting is, 
therefore, critical in this situation.43 
Xiong et al55 in their investigation and review on the 
management of AIS showed that emergent thrombectomy 
is a considerably effective treatment for patients suffering 
from large vessel occlusion during 6-8 hours of signs 
outset. Also, the time window for thrombectomy 
recommended being 24 hours among patients with acute 
posterior circulation large artery occlusion.
Conclusion
Many several advances have recently provided for the 
treatment of AIS. The evidence suggests that endovascular 
thrombectomy is substantially helpful for patients with 
underlying large vessel occlusion in both early and late 
stages of the disease. However, intravenous thrombolysis 
can still consider as an acute treatment for plenty of 
patients with AIS (those not candidates for thrombectomy 
or those deprived of thrombectomy). 
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